AKT1 and pulmonary fibrosis: Our pre-clinical and cellular research has demonstrated the therapeutic benefits of TCBN in pulmonary fibrosis [27,55], acute lung injury [28], and COVID-19 [24,56,57] via Akt-dependent and independent mechanisms.